Latham Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $SWIM in the last 7 days.
No SEC Form 4 filings for $SWIM in the last 30 days.
See all $SWIM insider activity →Cheplapharm, advised by Latham & Watkins, will acquire 20 medicines and three manufacturing sites from Sanofi. Sanofi will gain a 26.4% stake in Cheplapharm, with the deal expected to close in Q3 2027. Cheplapharm anticipates becoming the fifth-largest German pharma company upon completion.
Realty Income and KKR formed a joint venture to own European net-lease real estate assets. KKR will invest €528 million for a 49% stake, with Realty Income retaining 51%. The deal is expected to close by September 30, 2026. Latham & Watkins advised KKR on the transaction.
GSK agreed to acquire a trispecific T cell-engager from Chimagen Biosciences for up to $750M. The asset targets multiple myeloma, with phase I trials expected in 2027. GSK aims to improve tolerability and efficacy. Latham & Watkins advised on the deal.
Recent SWIM coverage spans mergers & acquisitions, corporate actions and financial news.
Cheplapharm, advised by Latham & Watkins, will acquire 20 medicines and three manufacturing sites from Sanofi. Sanofi will gain a 26.4% stake in Cheplapharm, with the deal expected to close in Q3 2027. Cheplapharm anticipates becoming the fifth-largest German pharma company upon completion.
Realty Income and KKR formed a joint venture to own European net-lease real estate assets. KKR will invest €528 million for a 49% stake, with Realty Income retaining 51%. The deal is expected to close by September 30, 2026. Latham & Watkins advised KKR on the transaction.
GSK agreed to acquire a trispecific T cell-engager from Chimagen Biosciences for up to $750M. The asset targets multiple myeloma, with phase I trials expected in 2027. GSK aims to improve tolerability and efficacy. Latham & Watkins advised on the deal.
Ares Alternative Credit committed over $2 billion to Eni for a long-term partnership on upstream infrastructure, advised by Latham & Watkins. The deal aims to boost Eni's cash generation and growth. Ares focuses on asset-based finance beyond traditional markets.
Beta Bionics (BBNX) priced a public offering of 7.65 million shares at $17.25 each and pre-funded warrants for 1.04 million shares at $17.2499, raising $150 million. The deal, expected to close by September 17, 2026, includes a 30-day over-allotment option. Latham & Watkins advised the underwriters.
AlphAI scores every news story that mentions SWIM with an AI model for sentiment and relevance, and aggregates insider trades from Latham Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cheplapharm, advised by Latham & Watkins, will acquire 20 medicines and three manufacturing sites from Sanofi. Sanofi will gain a 26.4% stake in Cheplapharm, with the deal expected to close in Q3 2027. Cheplapharm anticipates becoming the fifth-largest German pharma company upon completion.
2 min readRealty Income and KKR formed a joint venture to own European net-lease real estate assets. KKR will invest €528 million for a 49% stake, with Realty Income retaining 51%. The deal is expected to close by September 30, 2026. Latham & Watkins advised KKR on the transaction.
2 min readGSK agreed to acquire a trispecific T cell-engager from Chimagen Biosciences for up to $750M. The asset targets multiple myeloma, with phase I trials expected in 2027. GSK aims to improve tolerability and efficacy. Latham & Watkins advised on the deal.
2 min readAres Alternative Credit committed over $2 billion to Eni for a long-term partnership on upstream infrastructure, advised by Latham & Watkins. The deal aims to boost Eni's cash generation and growth. Ares focuses on asset-based finance beyond traditional markets.
2 min readBeta Bionics (BBNX) priced a public offering of 7.65 million shares at $17.25 each and pre-funded warrants for 1.04 million shares at $17.2499, raising $150 million. The deal, expected to close by September 17, 2026, includes a 30-day over-allotment option. Latham & Watkins advised the underwriters.
1 min readBKV Corporation (NYSE: BKV) priced a $575M offering of 1.625% convertible senior notes due 2031, upsized from $400M. Latham & Watkins advised the initial purchasers.
1 min readHanger, Inc. and Numotion, a portfolio company of AEA Investors, will merge to form Hanger Numotion, controlled by Patient Square Capital. Latham & Watkins advised the financing sources for the deal. Hanger provides orthotic and prosthetic services, while Numotion offers complex rehabilitation technology and mobility products in the US and Canada.
2 min readSimon Property Group, advised by Latham & Watkins, completed $800M in notes offerings. The deal involved two separate offerings. Details on the terms were not disclosed.
1 min readAres Alternative Credit committed over $2B to Eni for a long-term partnership on upstream infrastructure. Eni, a large upstream operator, aims to boost cash generation and growth. Latham & Watkins advised Ares on the deal.
1 min readBad Boy Mowers, backed by Sterling Group and TorQuest Partners, will acquire Hustler Turf Equipment from Stanley Black & Decker (SWK). The deal combines two major brands in the zero-turn mowers industry. Latham & Watkins LLP advised on the transaction.
2 min read
